Cite

MLA Citation

    Alana Dikopf et al.. “A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.” Expert opinion on drug safety, vol. 14, n.d., pp. 485–493. http://access.bl.uk/ark:/81055/vdc_100025120044.0x00005a
  
Back to record